Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTC01 vs FMT for Recurrent Clostridioides Difficile Infection
NCT05911997Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of MTC01 in Clostridioides difficile infection (CDI) (4 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Serious Adverse Events at 24 weeks and Adverse Events at 24 weeks. Started Jan 2024; status: completed.
02
Drugs
MTC01
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05911997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911997.